- Use of Anti-vascular Endothelial Growth Factors for Diabetic Retnopathy: National Health Insurance Claims Data
-
Cho S, Shin SJ, Suh JK, Tchoe H, Yang J, Kang MJ, Jee D
- KMID: 2453017
- J Korean Ophthalmol Soc.
- 2019 Jul;60(7):661-666.
- doi: 10.3341/jkos.2019.60.7.661
PURPOSE: To evaluate the current use of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with diabetic retinopathy. METHODS: We determined the current number of diabetic retinopathy patients and... -
- CITED
-
- Close
- SHARE
-
- Close
- Status of Usage of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration
-
Cho S, Shin SJ, Suh JK, Tchoe H, Kang MJ, Yang J, Jee D
- KMID: 2455458
- J Korean Ophthalmol Soc.
- 2019 Aug;60(8):758-764.
- doi: 10.3341/jkos.2019.60.8.758
PURPOSE: To evaluate the current use of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) in patients with age-related macular degeneration (AMD). METHODS: We analyzed the number and medical costs of... -
- CITED
-
- Close
- SHARE
-
- Close
- Final Impact of Anti-Vascular Endothelial Growth Factor Treatment in Age-related Macular Degeneration
-
Yang J, Shin SJ, Suh JK, Cho S, Tchoe H, Kang MJ, Jee D
- KMID: 2426365
- J Korean Ophthalmol Soc.
- 2018 Nov;59(11):1039-1048.
- doi: 10.3341/jkos.2018.59.11.1039
PURPOSE: To evaluate the effects of anti-vascular endothelial growth factor (VEGF) treatment on the healthcare-related finances of patients with age-related macular degeneration. METHODS: Changes in health care financing due to newly... -
- CITED
-
- Close
- SHARE
-
- Close
- Budget Impact Analysis of Anti-vascular Endothelial Growth Factor in Patients with Diabetic Macular Edema
-
Yang J, Shin SJ, Suh JK, Tchoe H, Cho S, Kang MJ, Jee D
- KMID: 2453018
- J Korean Ophthalmol Soc.
- 2019 Jul;60(7):667-675.
- doi: 10.3341/jkos.2019.60.7.667
PURPOSE: This study investigated the optimal strategy to minimize budgetary constraints on National Health Insurance (NHI) services, while maximizing the number of diabetic macular edema (DME) patients who receive anti-vascular... -
- CITED
-
- Close
- SHARE
-
- Close
- Meta-analysis of Intravitreal Injection of Anti-vascular Endothelial Growth Factors for Diabetic Macular Edema
-
Tchoe H, Shin SJ, Suh JK, Cho S, Yang J, Kang MJ, Jee D
- KMID: 2438073
- J Korean Ophthalmol Soc.
- 2019 Feb;60(2):144-151.
- doi: 10.3341/jkos.2019.60.2.144
PURPOSE: Intravitreal aflibercept, ranibizumab, bevacizumab, and dexamethasone are the most widely used drugs in the treatment of diabetic macular edema (DME). The aim of this study was to compare the... -
- CITED
-
- Close
- SHARE
-
- Close
- Intravitreal Injection of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration: a Systematic Review
-
Kang MJ, Shin SJ, Suh JK, Cho S, Tchoe H, Yang J, Jee D
- KMID: 2455457
- J Korean Ophthalmol Soc.
- 2019 Aug;60(8):748-757.
- doi: 10.3341/jkos.2019.60.8.748
PURPOSE: To compare the efficacy and safety of intravitreal injections of bevacizumab, ranibizumab, and aflibercept for the treatment of new patients with age-related macular degeneration (AMD). METHODS: We conducted an update... -
- CITED
-
- Close
- SHARE
-
- Close
